Total Funding
24
27
Total FundingPost-IPO Equity raised
Growth Score
-2 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
180678
Intersect ENT provides therapy solutions that enable ENT physicians to improve patients' quality of life.
Christine Davis-Kellerman: Director of Supply ChainPast Role: Accumetrics, Vice President, Operations
Robrt Binney: Chief Commercial OfficerPast Role: Aventis Pharmaceuticals, Medical Sales
About the Company
Intersect ENT Inc. (formerly Sinexus) is a medical device company pioneering novel therapies for Ear, Nose, and Throat surgeons to utilize in providing improved treatment for their patients. The company was founded in 2003 by Don Eaton and is headquartered in Menlo Park, California, United States.
